Squarepoint’s Repligen RGEN Stock Holding History

Squarepoint’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,500	Closed	-$521K	–	5418
2024 Q3	$521K	Sell	3,500 -100	-3%	-$14.3K	﹤0.01%	3061
2024 Q2	$454K	Buy	+3,600	New	+$564K	﹤0.01%	3147

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Squarepoint's RGEN Position: Q4 2025 in Review

Squarepoint sold out of Repligen (RGEN) in Q4 2025, closing a stake of 175,248 shares — an estimated $23.4M sold.

Squarepoint first reported a position in RGEN in Q3 2017 and held it in 22 quarters. The position peaked at $23.4M in Q3 2025. 473 funds tracked by Wall St. Rank hold RGEN as of Q4 2025.

Squarepoint reported no remaining Repligen position as of Q4 2025 after selling out during the quarter.
Squarepoint sold 175,248 Repligen shares in Q4 2025, an estimated $23.4M.
Squarepoint first reported a position in Repligen in Q3 2017 and held it in 22 quarters.
Squarepoint's Repligen position peaked at $23.4M in Q3 2025.
473 funds tracked by Wall St. Rank held Repligen as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.